articleMolecular TherapyMay 11, 2010HYBRID OA

Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms

Alnylam Pharmaceuticals (United States) · Max Planck Institute of Molecular Cell Biology and Genetics · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

Lipid nanoparticles (LNPs) have proven to be highly efficient carriers of short-interfering RNAs (siRNAs) to hepatocytes in vivo; however, the precise mechanism by which this efficient delivery occurs has yet to be elucidated. We found that apolipoprotein E (apoE), which plays a major role in the clearance and hepatocellular uptake of physiological lipoproteins, also acts as an endogenous targeting ligand for ionizable LNPs (iLNPs), but not cationic LNPs (cLNPs). The role of apoE was investigated using both in vitro studies employing recombinant apoE and in vivo studies in wild-type and apoE−/− mice. Receptor dependence was explored in vitro and in vivo using low-density lipoprotein receptor…

No related works found for this paper.

Funding